- Home
- NCMI vs ATXS Comparison
NCMI vs ATXS Comparison
Compare NCMI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- ATXS
- Stock Information
- Founded
- NCMI 2005
- ATXS 2008
- Country
- NCMI United States
- ATXS United States
- Employees
- NCMI N/A
- ATXS N/A
- Industry
- NCMI Advertising
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- ATXS Health Care
- Exchange
- NCMI Nasdaq
- ATXS Nasdaq
- Market Cap
- NCMI 648.2M
- ATXS 573.8M
- IPO Year
- NCMI 2007
- ATXS 2015
- Fundamental
- Price
- NCMI $6.68
- ATXS $11.12
- Analyst Decision
- NCMI Strong Buy
- ATXS Strong Buy
- Analyst Count
- NCMI 4
- ATXS 5
- Target Price
- NCMI $7.38
- ATXS $26.00
- AVG Volume (30 Days)
- NCMI 345.2K
- ATXS 310.9K
- Earning Date
- NCMI 08-05-2024
- ATXS 08-12-2024
- Dividend Yield
- NCMI N/A
- ATXS N/A
- EPS Growth
- NCMI N/A
- ATXS N/A
- EPS
- NCMI 1.74
- ATXS N/A
- Revenue
- NCMI $207,600,000.00
- ATXS N/A
- Revenue This Year
- NCMI $49.82
- ATXS N/A
- Revenue Next Year
- NCMI $16.54
- ATXS N/A
- P/E Ratio
- NCMI $3.85
- ATXS N/A
- Revenue Growth
- NCMI 5.97
- ATXS N/A
- 52 Week Low
- NCMI $3.51
- ATXS $4.26
- 52 Week High
- NCMI $7.01
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- NCMI 57.42
- ATXS 47.07
- Support Level
- NCMI $6.68
- ATXS $11.15
- Resistance Level
- NCMI $6.89
- ATXS $12.57
- Average True Range (ATR)
- NCMI 0.18
- ATXS 0.60
- MACD
- NCMI -0.06
- ATXS -0.09
- Stochastic Oscillator
- NCMI 26.67
- ATXS 20.94
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.